Sanara MedTech (SMTI) Projected to Post Earnings on Tuesday

Key Points

• Sanara MedTech is expected to release Q1 2026 results before the market opens on Tuesday, May 12, with analysts forecasting EPS of ($0.13) and revenue of $26.8 million and a conference call at 8:00 AM ET.
• In its last quarter (reported Mar. 24) the company missed estimates—EPS $0.04 vs. $0.11 expected—and remains unprofitable with a net margin of -36.42% and a negative return on equity of 20.73%, on $27.55 million in revenue.
• The stock trades near $19.64 with a market cap of $180 million, faces mixed analyst coverage (average rating "Hold" and consensus target $34), and has relatively low institutional ownership at about 8.1%.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.80 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last posted its earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The firm had revenue of $27.55 million during the quarter, compared to analyst estimates of $27.90 million.

Sanara MedTech Trading Up 3.4%

NASDAQ SMTI traded up $0.65 during trading hours on Tuesday, reaching $19.64. The company had a trading volume of 10,722 shares, compared to its average volume of 58,997. The company has a current ratio of 1.80, a quick ratio of 1.59 and a debt-to-equity ratio of 7.75. The stock has a market capitalization of $180.00 million, a P/E ratio of -4.64 and a beta of 1.16. The stock has a 50-day moving average of $18.89 and a 200 day moving average of $21.95. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95.

Institutional Trading of Sanara MedTech

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company's stock valued at $48,000 after purchasing an additional 1,171 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Sanara MedTech by 78.1% in the 4th quarter. Wells Fargo & Company MN now owns 3,322 shares of the company's stock worth $78,000 after acquiring an additional 1,457 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock valued at $89,000 after purchasing an additional 3,155 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Sanara MedTech by 171.1% during the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company's stock valued at $93,000 after purchasing an additional 2,515 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company's stock worth $101,000 after purchasing an additional 973 shares during the period. Institutional investors and hedge funds own 8.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SMTI. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Sanara MedTech in a research report on Monday, January 26th. Lake Street Capital began coverage on Sanara MedTech in a research report on Wednesday, April 15th. They set a "buy" rating and a $32.00 price objective on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sanara MedTech in a research note on Tuesday, April 21st. Wall Street Zen downgraded Sanara MedTech from a "buy" rating to a "hold" rating in a report on Sunday, April 5th. Finally, Zacks Research cut Sanara MedTech from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $34.00.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company's core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.